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Iijima’s 1991 discovery brought to the attention of the research community a new 
allotrope of carbon: carbon nanotubes (CNTs). Since then CNTs have been extensively studied 
and have demonstrated to be of great potential in various industrial and biomedical fields of 
application [1].  
CNTs can be described as rolled-up sheets of graphene forming single or multi walled 
seamless cylinders; their diameters range from few to hundreds of nanometres, respectively. They 
generally present a length/diameter ratio higher than 106 and have exceptional electrical, thermal, 
mechanical and optical properties [2,3]. Notwithstanding their great potential, the observed 
toxicity of these novel materials caused major concerns. CNTs are highly hydrophobic in nature 
and tend to form bundles in aqueous environments, leading to unstable dispersions. Bundles are 
phagocyted and cause cellular necrosis and oxidative stress damage. Furthermore, their 
characteristic shape, similar to asbestos fibres, is responsible for pulmonary toxicity that results in 
granulomas and fibrosis [4]. However, great advances have been achieved in the last decades in 
improving the water compatibility and reducing the toxicity of CNTs via both covalent and non-
covalent modification [5]. The strategies developed have allowed researchers to investigate 
numerous possible biomedical applications, including their use as drug carriers for anticancer 
drugs, gene therapy and as scaffold components in tissue engineering [4]. 
Carbon nanotubes as drug carriers 
The properties that make CNTs ideal drug carriers are multiple. CNTs have a high 
specific surface area per unit weight, offering enhanced loading capacity compared to 
conventional nanomaterials of spherical shape [6]. They have been used for the delivery of 
several anticancer drugs, with doxorubicin (DOX) being the most extensively studied. The 
possibility of forming π-π interactions between DOX and the surface of CNTs makes loading 
simple and efficient; furthermore, the high surface area offered by CNTs allows for a high degree 
of loading that cannot be achieved by other carrier systems. Using a non-covalent loading 
mechanism means that loading is not limited to type and number of functional groups present on 
the drug molecule and the carrier; moreover it allows for the loading of other lipophilic aromatic 
compounds (e.g. daunorubicin, camptothecin) [7]. Furthermore, pH dependent loading and 
release can be achieved so that the system can provide site specific release of the drug, thus 
increasing efficacy and reducing toxicity [8,9]. Studies on targeted drug delivery have now been 
conducted for over a century, since Ehrlich developed the concept of the “Magic Bullet” in 1906 
[10]. Many strategies have been employed from active targeting, by conjugation of monoclonal 
antibodies or smaller moieties recognised by a specific receptor (i.e. folate receptor 
overexpressed by certain types of tumours); to PEGylation and exploitation of the Enhanced 
Permeability and Retention (EPR) effect. After simple oxidation procedures in the presence of 
concentrated acids, CNTs provide multiple points amenable to chemical modification allowing 
for extensive and multiple functionalization [11]. Due to the ease of functionalization, targeting 
strategies used for polymeric and particulate carriers can been applied also to CNTs. However, a 
recent study has raised doubts about the possibility of achieving targeted drug delivery to cancer 
cells by the covalent attachment of folic acid to the surface of CNTs [11]. It is well known that 
CNTs are able to cross the cell membrane by virtue of their shape [12,13] and this could limit 
their applications in selective targeting. On the other hand, the literature is rich in examples that 
testify the contrary; therefore these findings highlight the need for further research to elucidate 
the role of CNTs in targeted drug delivery. Strategies that employ magnetically driven targeting 
[14] could offer a good alternative for selective targeting, even though they might result to be 
more expensive and more difficult to implement in a clinical setting. 
A further advantage in the use of CNTs is afforded by their strong absorption in the near 
infrared, Raman scattering and photoacoustic properties that can be exploited for imaging 
purposes providing an ideal tracking system for drug delivery or a diagnostics strategy [11,15]. 
Furthermore, since CNTs can emit heat when irradiated at near infrared wavelengths, their 
thermal properties have been exploited for causing local hyperthermia in photothermal ablation 
procedures for cancer therapy [16]. 
A new application avenue 
Most recently, an increased number of publications regard the potential use of CNTs in 
vaccine delivery. Initially, interest was sparked by the possibility of loading multiple antigens to 
the surface of CNTs and by their ability to rapidly internalise into antigen presenting cells [17]. 
However, more recently, it has become clear that the potential of CNTs is beyond that of an 
efficient carrier for vaccines. A genome-wide study, carried out comparing CNTs of different 
diameter and different surface functionalization, has highlighted their potential use as adjuvants 
and not just carriers for vaccine delivery [18]. This study observed that CNTs are able to boost 
pathways linked to the early innate response that are normally activated in response to infection, 
vaccination, transplant rejection and anti-tumour immune response suggesting their potential use 
in stimulating an effective inflammatory response, pathogen clearance and tumour rejection. 
CNTs have the potential of exceeding the performance of aluminium hydroxide as a vaccine 
adjuvant, since the latter is able to enhance the induction of the humoral immune response only, 
while CNTs have been shown to increase cell-mediated response [18]. 
A word of caution 
Very elegant, multifunctional, engineered CNTs derivatives and conjugates for drug 
delivery have been extensively described in literature. Constructs that combine drug loading 
properties with enhanced biocompatibility, targeting ability and imaging or tracking options have 
been developed to both exploit the positive and counteract the negative intrinsic properties of 
CNTs. However, the translational potential of nanomedicine so far has been achieved only by the 
simplest systems. Therefore, a paradigm shift is required; we need to move from sophisticated 
and elaborated ways of modifying CNTs to more simplified and flexible approaches. For 
example, favouring non-covalent modification could present an adaptable approach for the 
functinalisation of different types of CNTs and developing one pot functionalization methods 
could reduce development time and cost. Furthermore, despite intense research on carbon 
nanotubes there is still a wealth of unanswered questions about their interaction with the human 
body, more detailed and systematic studies need to be undertaken in this direction. Clinical 
applications are still not a reality however strategies to harvest the full potential of carbon 
nanotubes are continually invented, developed and refined as testified by the wealth of literature 
regularly published from experts in various biomedical specialities. 
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